Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas

Brief description of study

The purpose of the study is to determine the safety and efficacy of the study drugs called vemurafenib and cobimetinib. We want to know if genes can be affected in craniopharyngiomas and have found mutations or changes in the gene called BRAF. When BRAF is altered, it can cause a tumor to grow. In this study, the goal is to see if Vemurafenib and cobimetinib could shrink your tumor by at least one-quarter compared to its present size.


Clinical Study Identifier: s19-01872
ClinicalTrials.gov Identifier: NCT03224767


If you are registered as a volunteer, please login to the dashboard to send referrals.